Monte Rosa Therapeutics (NYSE: GLUE) — Perfil da empresa, notícias e dados financeiros
Monte Rosa Therapeutics focuses on molecular degradation to develop therapies for previously undruggable diseases, including cancer.
Monte Rosa Therapeutics
Monte Rosa Therapeutics (NASDAQ:GLUE) is dedicated to advancing the field of molecular degradation to develop innovative therapies for patients with diseases previously thought undruggable. Specializing in using small molecules to degrade disease-causing proteins, the company is at the forefront of creating a pipeline of projects aimed at a range of diseases, including cancer. Monte Rosa is driven by its objective to harness the power of its proprietary platform to bring life-changing treatments to those in urgent need, continually pushing the boundaries of what is possible in targeted therapy.
Resumo
Operações
Produtos e/ou serviços de Monte Rosa Therapeutics
- Development of molecular glue degraders designed to eliminate undruggable proteins associated with various cancers.
- Research in targeted protein degradation using small molecules to modulate protein levels for therapeutic purposes.
- Creation of a proprietary platform, QuEEN, for the discovery and development of novel E3 ligases.
- Partnerships with pharmaceutical companies to advance the development and commercialization of targeted therapies.
- Investment in precision medicine initiatives to tailor treatments to individual genetic profiles, improving efficacy and reducing side effects.
- Engagement in various oncology-focused clinical trials to validate the effectiveness of novel therapeutic approaches.
equipe executiva do Monte Rosa Therapeutics
- Markus WarmuthPresident, CEO & Director
- Philip NicksonChief Business & Legal Officer
- Filip JankuChief Medical Officer
- Matthew BowenCorporate Controller & Principal Accounting Officer
- Jennifer ChampouxChief Operating Officer
- Magnus WalterChief Technology Officer
- John C. CastleChief Data & Information Officer
- Sharon TownsonChief Scientific Officer
- Andrew FunderburkChief Investor Relations and Strategy Officer
Principais indicadores financeiros
Resultados divulgados pela Monte Rosa Therapeutics, em USD.
- Cap. de mercado
- 909,4 mi
- Receita (TTM)
- 28,7 mi
- P/L
- —
- LPA (diluído, TTM)
- -1.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 123,7 mi | -54,2 mi | -38,6 mi | |
| 75,6 mi | -81,1 mi | -72,7 mi | |
| 0 | -143,3 mi | -135,4 mi | |
| 0 | -112,4 mi | -108,5 mi |